Published in Ann Nucl Med on June 01, 2004
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry (2012) 0.97
Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology (Berl) (2013) 0.85
Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. Synapse (2009) 0.84
Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry (2006) 0.83
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology (Berl) (2008) 0.77
Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol (2010) 0.77
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology (2002) 3.16
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
(18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med (2004) 2.32
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer (2014) 2.12
The effect of nitroglycerin on myocardial blood flow in various segments characterized by rest-redistribution thallium SPECT. J Nucl Med (2003) 2.02
[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia (2005) 1.78
Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release (2012) 1.50
Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med (2011) 1.45
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging (2012) 1.44
Quantification in SPECT cardiac imaging. J Nucl Med (2003) 1.41
Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent. Eur J Nucl Med Mol Imaging (2003) 1.40
Cardiac functional analysis with multi-detector row CT and segmental reconstruction algorithm: comparison with echocardiography, SPECT, and MR imaging. Radiology (2005) 1.39
Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys Med Biol (2008) 1.36
Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med (2002) 1.30
Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer. Cancer Sci (2009) 1.29
Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol (2002) 1.27
Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med (2002) 1.26
In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol (2009) 1.26
F-18 FDG PET of foreign body granuloma: pathologic correlation with imaging features in 3 cases. Clin Nucl Med (2010) 1.25
Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol (2006) 1.22
Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem (2008) 1.18
Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med (2007) 1.17
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol (2006) 1.16
Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) (2009) 1.15
Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med (2006) 1.13
Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability--analysis in hypercholesterolemic rabbits. Atherosclerosis (2007) 1.13
Liliequist membrane: three-dimensional constructive interference in steady state MR imaging. Radiology (2003) 1.12
Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron. Nucl Med Biol (2003) 1.11
In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands. Bioconjug Chem (2009) 1.11
Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med (2006) 1.10
GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun (2009) 1.10
Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality". Ann Nucl Med (2003) 1.09
Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide. J Nucl Med (2013) 1.08
Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol (2009) 1.07
Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res (2010) 1.03
Development and evaluation of a low-cost and high-capacity DICOM image data storage system for research. J Digit Imaging (2010) 1.03
Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med (2008) 1.02
What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med (2011) 1.02
Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci (2009) 1.02
Molecular probes for the in vivo imaging of cancer. Mol Biosyst (2009) 1.01
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med (2004) 1.01
Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol (2009) 1.00
Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem (2011) 1.00
New approaches to lymphatic imaging. Lymphat Res Biol (2009) 0.99
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging (2011) 0.99
Cortical correlates of vestibulo-ocular reflex modulation: a PET study. Brain (2003) 0.98
Immature teratoma of the ovary: correlation of MR imaging and pathologic findings. Eur Radiol (2002) 0.98
Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology (2010) 0.98
Quantitative analysis of pharmaceutical drug distribution in multiple organs by imaging mass spectrometry. Rapid Commun Mass Spectrom (2012) 0.98
Percutaneous radiofrequency ablation therapy after intrathoracic saline solution infusion for liver tumor in the hepatic dome. J Vasc Interv Radiol (2002) 0.97
Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci (2006) 0.97
X-ray computed tomography contrast agents prepared by seeded growth of gold nanoparticles in PEGylated dendrimer. Nanotechnology (2010) 0.96
Development of injectable O-15 oxygen and estimation of rat OEF. J Cereb Blood Flow Metab (2003) 0.96
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother (2008) 0.96
MR contrast of ferritin and hemosiderin in the brain: comparison among gradient-echo, conventional spin-echo and fast spin-echo sequences. Eur J Radiol (2003) 0.95
Applicability of a high-resolution small semiconductor gamma camera to small animal imaging. Nucl Med Commun (2007) 0.95
Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med (2005) 0.94
Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. Kidney Int (2002) 0.94
Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem (2005) 0.94
Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis. J Med Chem (2010) 0.94
BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci (2012) 0.93
MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients. Eur Radiol (2002) 0.93
Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of beta-amyloid plaques in Alzheimer's disease. J Med Chem (2009) 0.93
Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET. Eur J Nucl Med Mol Imaging (2002) 0.93
Radiolabelled probes for imaging of atherosclerotic plaques. Am J Nucl Med Mol Imaging (2012) 0.93
Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med (2004) 0.93